After 4 weeks of treatment, sulindac treatment significantly reduced tumor growth, improved the inflammatory state in KpB mice, and decreased the expression of Ki-67, Cox-2 and Bcl-2 in OC tissues. Here, BCL2 is linked to neoplasm.